Display options
Cite
Tanita K, Fujimura T, Kakizaki A, et al. Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling. Case Rep Dermatol. 2015;7(2):166-70doi: 10.1159/000437415.
Tanita, K., Fujimura, T., Kakizaki, A., Furudate, S., Kusakari, Y., & Aiba, S. (2015). Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling. Case reports in dermatology, 7(2), 166-70. https://doi.org/10.1159/000437415
Tanita, Kayo, et al. "Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling." Case reports in dermatology vol. 7,2 (2015): 166-70. doi: https://doi.org/10.1159/000437415
Tanita K, Fujimura T, Kakizaki A, Furudate S, Kusakari Y, Aiba S. Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling. Case Rep Dermatol. 2015 Jul 24;7(2):166-70. doi: 10.1159/000437415. eCollection 2015. PMID: 26351425; PMCID: PMC4560327.
Copy Download .nbib Format: NLM
Share it on

Case Rep Dermatol. 2015 Jul 24;7(2):166-70. doi: 10.1159/000437415. eCollection 2015.

Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling.

Case reports in dermatology

Kayo Tanita, Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Yoshiyuki Kusakari, Setsuya Aiba

Affiliations

  1. Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

PMID: 26351425 PMCID: PMC4560327 DOI: 10.1159/000437415

Abstract

Abatacept is a biological immune modifier that is used for the treatment of rheumatoid arthritis. Although psoriasiform drug eruption is reported as one of the cutaneous adverse effects of abatacept, the precise mechanisms are not fully understood. In this report, we describe a 65-year-old Japanese man with psoriasiform drug eruption caused by abatacept. Interestingly, immunohistochemical staining revealed that the epidermal keratinocytes in the basal layer and lower layers of the stratum spinosum were positive for pSTAT3, partially positive for pSTAT1 and negative for pSTAT6, which is similar to conventional psoriasis vulgaris. Our present study suggests that psoriasiform drug eruption caused by abatacept might develop by similar immunological mechanisms as those of psoriasis vulgaris.

Keywords: Interleukin 17; Psoriasiform drug eruption; Psoriasis vulgaris; pSTAT3

References

  1. J Eur Acad Dermatol Venereol. 2012 Feb;26(2):257-8 - PubMed
  2. N Engl J Med. 2014 Jul 24;371(4):326-38 - PubMed
  3. Acta Derm Venereol. 2011 May;91(3):362-3 - PubMed
  4. Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):92-3 - PubMed
  5. J Am Acad Dermatol. 2014 Jul;71(1):141-50 - PubMed
  6. J Dermatolog Treat. 2015;26(6):493-501 - PubMed
  7. PLoS One. 2009;4(3):e5087 - PubMed
  8. Br J Dermatol. 2011 Nov;165(5):990-6 - PubMed

Publication Types